China's first cancer immunotherapy will cost half of what it costs in the U.S.

China's first cancer immunotherapy will cost half of what it costs in the U.S.

STAT Plus: China’s first cancer immunotherapy will be priced at about half of what it costs in the U.S.

By REBECCA ROBBINS

MEL EVANS/AP

The blockbuster cancer drug Opdivo, made by Bristol-Myers Squibb, will be sold for about $84,000 per year in the Chinese market, before discounts.

READ MORE